Asia Pacific Newborn Screening Market, by Products Type (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022

Code : CMI2546

Pages :193

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Market Challenges And Opportunities

Asia Pacific Newborn Screening Market: Restraint

The major factors that hinder growth of the Asia pacific newborn screening market include lack of improvement in healthcare infrastructure and trained professionals. Newborn screening is still not widely adopted in Asia Pacific region and requires more development and awareness. Countries in Asia Pacific region have high population and less number of trained professionals. High population with low and middle-income level and poor quality health services are hindering growth of the market.

Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market

Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in January 2022, Trivitron, medical devices company, informs that implementation of newborn screening at the national level will help to identify the infants who need urgent medical care at a much larger scale. Newborn screening is a program that facilitates the early detection of several genetic, endocrine, and metabolic disorders.

Furthermore, in March 2018, Under National Rural Health Mission, significant progress had been made in reducing mortality in children. Whereas, there is an advance in reducing child mortality there is a dire need to improving survival outcome. This would be reached by early detection and management of conditions that were not addressed comprehensively in the past. Indian Government started the RASHTRIYA BAL SWASTHYA KARYAKRAM (RBSK) in 2019 for the early diagnosis of genetic, endocrine and metabolic disorders. Rashtriya Bal Swasthya Karyakram (RBSK) is an important initiative aiming at early identification and early intervention for children from birth to 18 years to cover 4 ‘D’s namely defects at birth, deficiencies, diseases, development delays including disability.

Increasing use of advanced technology for newborn screening is expected to drive the market over the forecast period.

Technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analysis and high adoption rate of newborn screening with new technology are factors that are expected to drive growth of the market. In October 2018, LifeCell International, India’s leading stem cell bank and mother & baby diagnostics company, launched RightStart, the world’s first integrated DNA testing for newborn screening to detect over 50 medical conditions.